“…Of the 46 interventions included, nearly half ( n = 22, 48%) were conducted in Europe [ 27 – 48 ], followed by North America ( n = 20, 43%) [ 14 , 15 , 49 – 66 ], Australia ( n = 3, 7%) [ 67 – 69 ], and the Philippines ( n = 1, 2%) [ 70 ]. Most interventions targeted patients with a mix of cancer types ( n = 24, 52%) [ 14 , 15 , 27 , 30 , 35 , 37 , 40 , 41 , 46 , 47 , 51 , 52 , 54 , 55 , 60 – 63 , 65 – 70 ], followed by a focus on head and neck ( n = 4, 8%) [ 31 , 32 , 48 , 53 ], gynecologic ( n = 3, 7%) [ 49 , 57 , 58 ], lung ( n = 3, 7%) [ 39 , 56 , 59 ], and breast ( n = 3, 7%) [ 28 , 42 , 64 ] cancers. Of the 46 ePSM studies, 33% ( n = 15) explicitly used implementation science in their design, data collection, or analysis [ 30 , 32 , 35 , 41 , 44 , 46 , 50 , 51 , 53 – 55 , 58 , 60 , 67 , 69 ], while 67% ( n = 31) reported on the implementation of an ePSM but did not use an implementation science approach [ 14 , 15 , 27 – 29 , 31 , 33 , 34 , ...…”